Tesamorelin – 10 mg
| Quantity | Price | Discount |
|---|---|---|
| 2 | $67.90 | 3% |
| 5 | $65.80 | 6% |
| 10 | $62.30 | 11% |
| 11+ | $60.90 | 13% |
$70.00
What is Tesamorelin?
Tesamorelin is a synthetic analog of growth hormone–releasing hormone (GHRH)
consisting of 44 amino acids. It is primarily researched for its ability to stimulate the pituitary gland
to increase endogenous growth hormone secretion. Tesamorelin has been studied extensively for reducing visceral adipose tissue,
particularly in HIV-associated lipodystrophy, and continues to be investigated for broader metabolic and age-related applications.
Tesamorelin Structure
| Peptide Name | Tesamorelin |
|---|---|
| Synonyms | TH9507 |
| Sequence | Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Gln-Gly-Ser-Ser-Ser-Gly-Ala-Pro-Gly-Gly-Gly-Ser-NH2 |
| Molecular Formula | C221H366N72O67S |
| Molecular Weight | 5135.9 g/mol |
Tesamorelin Research
1. Tesamorelin and Visceral Fat Reduction
Tesamorelin has been FDA-approved for reducing visceral adipose tissue in patients with HIV-associated lipodystrophy.
Clinical trials show significant reductions in abdominal fat while preserving subcutaneous fat and lean muscle mass.
2. Tesamorelin and Growth Hormone Secretion
By stimulating the pituitary gland to release growth hormone, Tesamorelin promotes IGF-1 production,
which supports protein synthesis, lipid metabolism, and tissue repair.
3. Cognitive and Metabolic Effects
Preliminary studies suggest potential benefits in cognitive function, lipid regulation, and metabolic health,
making Tesamorelin a candidate for broader research beyond HIV-related conditions.
Future Tesamorelin Research
Ongoing studies are examining Tesamorelin for its potential role in treating non-alcoholic fatty liver disease (NAFLD),
metabolic syndrome, and age-related decline in growth hormone production.
Further research may clarify its use in healthy aging, muscle preservation, and neuroprotection.
Tesamorelin Resources
- Falutz J, et al. – “Metabolic effects of Tesamorelin in HIV-infected patients with abdominal fat accumulation.” NEJM, 2010.
- Clinical trials on Tesamorelin and visceral adipose tissue reduction.
- Research on cognitive and hepatic outcomes related to GHRH analogs.
Related Products
CJC-1295 w/ DAC – 5 mg (10 Vials/Kit)
Recently Viewed
Reviews
There are no reviews yet.